Insider Buying: Lipocine (NASDAQ:LPCN) Director Buys $19,429.55 in Stock

Lipocine Inc. (NASDAQ:LPCN) Director John Higuchi acquired 9,037 shares of the company’s stock in a transaction that occurred on Tuesday, September 29th. The stock was purchased at an average price of $2.15 per share, for a total transaction of $19,429.55. Following the purchase, the director owned 225,395 shares of the company’s stock, valued at $484,599.25. The trade was a 4.18% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Lipocine Trading Down 1.0%

Shares of NASDAQ LPCN opened at $2.05 on Friday. The stock has a fifty day simple moving average of $2.17 and a two-hundred day simple moving average of $2.73. Lipocine Inc. has a 1-year low of $1.81 and a 1-year high of $12.37. The firm has a market cap of $16.90 million, a price-to-earnings ratio of -1.15 and a beta of 0.40.

Lipocine (NASDAQ:LPCN) last issued its earnings results on Tuesday, August 4th. The specialty pharmaceutical company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.08. Lipocine had a negative return on equity of 64.75% and a negative net margin of 755.39%.The firm had revenue of $0.19 million for the quarter, compared to analyst estimates of $0.21 million. Analysts forecast that Lipocine Inc. will post -1.54 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the company. Wall Street Zen upgraded Lipocine from a “sell” rating to a “hold” rating in a research note on Saturday, July 18th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Lipocine in a research report on Tuesday, September 22nd. Weiss Ratings upgraded shares of Lipocine from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, September 24th. Finally, HC Wainwright reissued a “neutral” rating and issued a $4.00 price target on shares of Lipocine in a research report on Monday, September 21st. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $4.00.

Institutional Trading of Lipocine

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Eversept Partners LP purchased a new stake in shares of Lipocine in the first quarter worth about $2,357,000. AIGH Capital Management LLC purchased a new position in Lipocine during the first quarter valued at approximately $1,598,000. Stempoint Capital LP purchased a new position in Lipocine during the first quarter valued at approximately $1,282,000. Seven Fleet Capital Management LP bought a new stake in Lipocine during the 1st quarter worth approximately $998,000. Finally, Persistent Asset Partners Ltd bought a new stake in Lipocine during the 4th quarter worth approximately $567,000. 9.11% of the stock is currently owned by institutional investors.

Lipocine Company Profile

Lipocine Inc is a clinical-stage biopharmaceutical company based in Salt Lake City, Utah, focused on developing oral therapies for conditions that have traditionally been treated with injections or other less convenient formulations. The company uses its proprietary Lip’ral drug-delivery technology to improve the absorption and administration of certain active pharmaceutical ingredients.

Lipocine’s lead product, TLANDO (testosterone undecanoate), is an oral testosterone-replacement therapy approved by the U.S.